Tue. 7 May 2024, 5:07pm ET
Benzinga
Earnings, Earnings Misses, News
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses of $(0.53) per share from the same period last year. The company reported $986.000 thousand in sales this quarter. This is a 63.79 percent decrease over sales of $2.723 million the same period last year.